Premium
Rediscovery of NF‐κB signaling in nasopharyngeal carcinoma: How genetic defects of NF‐κB pathway interplay with EBV in driving oncogenesis?
Author(s) -
Yi Mei,
Cai Jing,
Li Junjun,
Chen Shengnan,
Zeng Zhaoyang,
Peng Qian,
Ban Yuanyuan,
Zhou Ying,
Li Xiaoling,
Xiong Wei,
Li Guiyuan,
Xiang Bo
Publication year - 2018
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.26410
Subject(s) - nasopharyngeal carcinoma , carcinogenesis , biology , cancer research , nf κb , signal transduction , cancer , immune system , inflammation , immunology , genetics , medicine , radiation therapy
Nasopharyngeal carcinoma (NPC) is a unique EBV‐associated subtype of head and neck cancer, which has the highest incidence in Southern China and eastern South Asia. The interaction between genetic risk factors and environmental challenge, have been considered to contribute to the development of nasopharyngeal carcinogenesis. Constitutive activation of NF‐κB signaling has been seen in NPC tissues and is associated with unfavorable prognosis. Recently, several whole exome sequencing study consistently revealed that high frequency mutations of NF‐κB pathway negative regulators is common in nasopharyngeal carcinoma, which reinforce the importance of NF‐κB driving oncogenesis. This review focuses on the current state of research in role of NF‐κB in NPC carcinogenesis. We summarized the newly identified loss of function (LOF) mutations on NF‐κB negative regulators leading to it's activation bypass LMP‐1 stimulation. We discussed the critical role of NF‐κB activation in immortalization and transformation of nasopharygeal epithelium. We also depicted how NF‐κB signaling mediated chronic inflammation contribute to persistent EBV infection, immune evasion of EBV infected cells, metabolic reprogramming, and cancer stem cells (CSCs) formation in NPC. Lastly, we discussed the clinical resonance of targeting NF‐κB for NPC precise therapy.